April 1, 2021
Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications:
- W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine
- Jouni Uitto, M.D., Ph.D., Professor of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, and Chair of the Department of Dermatology and Cutaneous Biology at The Sidney Kimmel Medical College at Thomas Jefferson University, in Philadelphia, Pennsylvania
- Paul B. Yu, M.D., Ph.D., Section Head of Cardiovascular Life Sciences at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School
David Thompson, M.A., M.S., Ph.D., a senior adviser to Inozyme, who served as Inozyme’s Senior Vice President and Chief Scientific Officer from 2018-2020, will also be joining the SAB.
Enrique M. De La Cruz, Ph.D., Jon S. Morrow, M.D., Ph.D., and Mark A. Lemmon, Ph.D. are stepping down from the SAB, effective immediately.
“We are honored to welcome Charles, Jouni, and Paul, to Inozyme, and we are excited to have David accept this new role on our scientific advisory board. Their combined experience in ABCC6 deficiency, neointimal proliferation, and mineralization diseases with low pyrophosphate will be invaluable as we continue to explore the role of ENPP1 in new and intriguing indications,” said Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer of Inozyme Pharma. “Inozyme is deeply thankful to Enrique, Jon, and Mark for their valuable advice and counsel through the early years.”
W Charles O’Neill IV, M.D., is an accomplished physician-scientist in the Renal Division at Emory University School of Medicine where he leads an active basic and translational research program. His current research focuses on the pathophysiology of vascular calcification in renal failure, specifically examining the role of endogenous pyrophosphate in the etiology of vascular calcification.
Jouni Uitto, M.D., Ph.D., is currently Professor of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, and Chair of the Department of Dermatology and Cutaneous Biology at The Sidney Kimmel Medical College at Thomas Jefferson University, in Philadelphia, Pennsylvania. He is also Director of the Jefferson Institute of Molecular Medicine at Thomas Jefferson University. Dr. Uitto is internationally recognized for his research on connective tissue biochemistry and molecular biology in relation to cutaneous diseases and skin aging with a special interest in Pseudoxanthoma Elasticum (PXE), also known as ABCC6 deficiency.
Paul B. Yu, M.D., Ph.D., is a physician-scientist at Brigham and Women’s Hospital and an Associate Professor of medicine at Harvard Medical School. Dr. Yu’s clinical focus areas include cardiovascular disease, pulmonary vascular disease, and cardiovascular disease related to rheumatologic conditions. His research explores how signaling via the bone morphogenetic protein (BMP), activin, growth and differentiation factor (GDF), and TGF-beta signaling pathways regulate the consequences of injury and inflammation in cardiovascular, musculoskeletal, and metabolic diseases.
The new and expanded SAB and the Clinical Advisory Board (CAB) of Inozyme is as follows:
|Yves Sabbagh, Ph.D., Chair||Inozyme Pharma (Senior Vice President and Chief Scientific Officer)|
|Demetrios Braddock, M.D. Ph.D.||Yale University School of Medicine|
|Charles O’Neill, M.D.||Emory University School of Medicine|
|Joseph Schlessinger, Ph.D.||Yale University School of Medicine|
|Ed Skolnik, M.D.||New York University Langone Medical Center|
|Robert Terkeltaub, M.D.||UC San Diego School of Medicine (UCSD)|
|David Thompson, M.A., M.S., Ph.D.||Inozyme Pharma (Senior Advisor)|
|Jouni Uitto, M.D., Ph.D.||The Sidney Kimmel Medical College at Thomas Jefferson University|
|Paul B. Yu, M.D., Ph.D||Brigham and Women’s Hospital and Harvard Medical School|
|Michael A. Levine, M.D., Chair||The Children’s Hospital of Philadelphia (CHOP)|
|Thomas O. Carpenter, M.D.||Yale University School of Medicine|
|Frank Rutsch, M.D.||Münster University Children’s Hospital|